If you’re eyeing Novavax (NVAX) today, you’re not alone, and the reason is clear. Investors are buzzing after the company announced a refinancing deal that pushes out most of its convertible debt from ...

Novavax has experienced a significant decline in its stock price, dropping by 19.26% over the past week. This downturn comes despite recent positive developments, including a $175 million milestone ...

Pfizer's JN.1 vaccine has been the only option available to Australians since the start of the year. Here's what happened to ...

Although infection prevention is an essential part of every rheumatologist’s routine, balancing efficacy, risk and individual patient choices — all while contending with a seemingly constant flow of ...

As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...

Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, ...

A presumably unvaccinated fraction of homeschooled children dispersed throughout Santa Barbara County does not pose a threat ...

BofA forecasts slowing overall revenue, estimating about $1 billion in 2025, slightly below the company’s guidance. It ...

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

American Academy of Pediatrics updates immunization guidelines, and recommends COVID-19 vaccines for young children, ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is ...

If you want a COVID-19 shot this fall, will your employer’s health insurance plan pay for it? There’s no clear answer.